San Carlos, CA, United States of America

Thomas F Woiwode


Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 71(Granted Patents)


Location History:

  • Menlo Park, CA (US) (2006 - 2009)
  • San Carlos, CA (US) (2007 - 2009)
  • San Francisco, CA (US) (2010)

Company Filing History:


Years Active: 2006-2010

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Thomas F Woiwode: Innovator in Pharmaceutical Sciences

Introduction

Thomas F Woiwode is a notable inventor based in San Carlos, CA (US). He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of gemcitabine prodrugs. With a total of 6 patents to his name, Woiwode's work has the potential to impact the treatment of various diseases.

Latest Patents

Woiwode's latest patents focus on gemcitabine prodrugs, which are designed to enhance the efficacy of gemcitabine in treating or preventing diseases such as cancer and viral infections. His inventions include methods of making gemcitabine prodrugs, pharmaceutical compositions containing these prodrugs, and methods for their use in medical treatments. These innovations represent a significant advancement in the pharmaceutical industry.

Career Highlights

Woiwode is currently associated with Xenoport, Inc., where he continues to develop innovative solutions in the pharmaceutical sector. His expertise and dedication to research have positioned him as a key figure in the field.

Collaborations

Throughout his career, Woiwode has collaborated with talented individuals such as Mark A Gallop and Ge Peng. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Thomas F Woiwode's contributions to pharmaceutical sciences through his innovative patents highlight his role as a leading inventor in the industry. His work continues to pave the way for new treatments that can improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…